'Reshaped manufacturing' means continued investment in biologics capacity, AstraZeneca
Plans to reshape its manufacturing network will include increasing biologics capacity beyond its recent acquisitions and expansions, says AstraZeneca.
Archives for May 2, 2016
Shire: ‘Baxalta brings us world-class manufacturing network’
Shire will retain Baxalta’s biologics expertise and continue assessing its manufacturing network following the completion of its $32bn acquisition, expected next month.
Octapharma recalls Octagam lot in US
Octapharma has withdrawn one lot of its immune deficiency treatment Octagam after receiving reports of reports of allergic skin reactions in patients treated with the product.
Goodwin selected to make bispecific antibody candidate for Russian firm
Distance and time differences are not barriers when choosing a biologics CMO, says Goodwin Biotechnology which has won a bispecific antibody process and scale-up contract from Russia’s IBC Generium.
Samsung on Samsung: Bioepis selects Biologics as a biosimilars CMO
Samsung Biologics has been contracted by its joint venture entity Samsung Bioepis to manufacturer biosimilars from its facility in Korea.